Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) Non Operating Income (2018 - 2025)

Cue Biopharma's Non Operating Income history spans 8 years, with the latest figure at $147000.0 for Q3 2025.

  • For Q3 2025, Non Operating Income fell 5.77% year-over-year to $147000.0; the TTM value through Sep 2025 reached $479000.0, down 55.97%, while the annual FY2024 figure was $826000.0, 41.67% down from the prior year.
  • Non Operating Income for Q3 2025 was $147000.0 at Cue Biopharma, down from $153000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $414000.0 in Q3 2023 and bottomed at -$118000.0 in Q2 2022.
  • The 5-year median for Non Operating Income is $147000.0 (2025), against an average of $150784.1.
  • The largest YoY upside for Non Operating Income was 6929.25% in 2022 against a maximum downside of 591.67% in 2022.
  • A 5-year view of Non Operating Income shows it stood at $3898.0 in 2021, then skyrocketed by 6929.25% to $274000.0 in 2022, then surged by 45.62% to $399000.0 in 2023, then plummeted by 65.66% to $137000.0 in 2024, then grew by 7.3% to $147000.0 in 2025.
  • Per Business Quant, the three most recent readings for CUE's Non Operating Income are $147000.0 (Q3 2025), $153000.0 (Q2 2025), and $42000.0 (Q1 2025).